Bayer Advances DAROLUTAMIDE Submission to EMA for New Use
Bayer's Application for Darolutamide in Europe
Orion Corporation's collaboration partner Bayer has taken a significant step recently by submitting an application to the European Medicines Agency (EMA) for darolutamide. This crucial oral androgen receptor inhibitor is being proposed for use in patients with metastatic hormone-sensitive prostate cancer (mHSPC) when combined with androgen deprivation therapy (ADT).
Positive Results from Phase III Trials
The application highlights the promising outcomes from the pivotal Phase III ARANOTE trial. This significant study revealed that the combination of darolutamide and ADT led to a 46% decrease in the risk of radiological progression or death compared to those treated solely with a placebo and ADT. Such results are pivotal, as they open new avenues for combating mHSPC more effectively.
Diverse Approvals Across the Globe
Darolutamide is not a new entrant in the market. The compound has already been approved in more than 80 countries under the brand name Nubeqa™, where it is used together with ADT and docetaxel for treating mHSPC. Additionally, it boasts approval in over 85 other countries for preventing the progression of non-metastatic castration-resistant prostate cancer (nmCRPC) in high-risk patient groups.
Joint Development and Future Trajectory
The development journey of darolutamide is a testament to the collaborative strength between Orion Corporation and Bayer. Both companies are working diligently to ensure that this innovative treatment reaches the patients who need it the most. With ongoing research and positive initial results, the future looks promising for darolutamide and its potential role in prostate cancer management.
Contact Information
For those interested in learning more about Orion Corporation or their innovative treatments, Tuukka Hirvonen is available for inquiries. As part of Investor Relations, he can be reached at +358 10 426 2721.
About Orion Corporation
Orion Corporation is a well-established Finnish pharmaceutical entity with over a century of experience in enhancing well-being. The company focuses on developing, manufacturing, and marketing both human and veterinary pharmaceuticals, along with active pharmaceutical ingredients. Orion's expansive portfolio includes proprietary and generic medications as well as consumer health products, emphasizing oncology and pain treatment. In the previous fiscal year, Orion recorded net sales of EUR 1,190 million, employing approximately 3,600 staff by year-end. The company's shares, designated as A and B, are traded on Nasdaq Helsinki.
Frequently Asked Questions
What is darolutamide used for?
Darolutamide is primarily used for the treatment of prostate cancer, particularly in metastatic hormone-sensitive cases and high-risk non-metastatic settings.
Who developed darolutamide?
Darolutamide was developed jointly by Bayer and Orion Corporation.
In how many countries is darolutamide approved?
Darolutamide has received approval in over 80 countries globally, under the brand name Nubeqa™.
What were the results of the ARANOTE trial?
The ARANOTE trial demonstrated a 46% reduction in the risk of radiological progression or death for patients using darolutamide with ADT.
How can I contact Orion Corporation?
For inquiries, you can reach Tuukka Hirvonen from Investor Relations at +358 10 426 2721.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Boeing's Workforce Restructuring Amidst Strike and Losses
- Mixed Futures Ahead of Key Earnings; Investors Watch Economy
- Horizon Robotics Readies for Major IPO Backed by Tech Giants
- Top Dividend Stocks to Watch in the Coming Decade
- Benitec Biopharma Enhances Webcast Details for Investors
- Investor Anticipation Grows Ahead of Earnings Reports
- Nokia Partners with Windstream and Colt for Groundbreaking Trial
- Innovative Wirex Pay Launches Node Rewards for DeFi Users
- Insights into Comstock Inc.’s Upcoming Earnings Call
- Promoting Safe Movement: HomeCEU's Insights for Therapists
Recent Articles
- Danske Bank's Share Buyback Update for Week 41: Insights
- Municipality Finance to Redeem Early Bonds Under MTN Program
- International Petroleum Corporation's Share Buyback Highlights
- Alm. Brand Sets Coupon Rate for Tier-1 Bonds in 2024
- Adviser's Insights on Trump's Economic Vision and Dollar Strength
- Transforming Smart Farming with agrirouter 2.0: A New Era
- Market Optimism Surge: Wells Fargo and JPMorgan Earnings Highlight Growth
- Expert Analysts Predict Significant Upside for AMD and Others
- HL Holdings Innovates Parking Solutions with Stanley Robotics
- Iconic Banksy Works to be Auctioned in Exclusive Event
- Envision Earns Second Spot on Fortune's Global Change Makers List
- RBC Updates Hays Plc Price Target Amid Market Challenges
- European Equity Fund Achieves Remarkable Success Without Tech
- Sisecam Advocates for Industry Collaboration in Soda Ash Sector
- Neurocrine Biosciences Announces Major Leadership Change
- Tracon Pharmaceuticals Implements Super-Voting Mechanics
- Discover Hikvision's Advanced ColorVu 3.0 Network Cameras
- RBC Capital Highlights Smith & Nephew's Stock As A Strong Buy
- Guzman y Gomez Navigates U.S. Challenges While Expanding
- BioCity's SC0062 to Present Promising Clinical Results Soon
- Duolingo Faces Stock Rating Shift Amid Product Growth
- Turkcell and ZTE Achieve Revolutionary Breakthrough in Networking
- Canaccord's Positive Outlook on Tyro Payments and Future Growth
- Global Economic Perspectives: Data, Rates, and Market Sentiments
- France's Budget Challenges and Financial Outlook for Investors
- COMAC's C909 Regional Jet Marks New Era in Aviation Branding
- Chinese Property Market Shows Signs of Hope Amidst Uncertainty
- Fitch Predicts Trump Presidency's Economic Impact on Asia
- Market Trends: Insights on Earnings, Boeing Cuts, and More
- European Stocks Steady Amid China Economic Stimulus Hiccups
- Alm. Brand A/S Weekly Update on Share Buyback Initiatives
- Insights on Early Redemptions in Jyske Realkredit Bonds
- Celebrating Community and Sports at Cyclothon 2024 Event
- Volkswagen Faces EV Sales Challenges but China Shows Growth
- Revolutionizing Expense Management with Real-Time Card Tech
- Innovative Tidal Energy Project Takes Shape in the North Atlantic
- Envision Energy Secures Recognition as a Global Innovator Again
- Pioneering Tidal Energy Development Expands in Hestfjord
- Bruynzeel Storage Systems Welcomes Eelco Ockers as CEO
- Rising Butter Prices Challenge Bakers Amid Holiday Preparations
- BofA Securities Rates Elia Group as 'Underperform' Amid Challenges
- Navigating European Markets: Focus on Chinese Stimulus Plans
- Boeing's Troubles Intensify Amidst Potential Workforce Cuts
- Eckoh plc Trading Disclosure and Market Updates
- Mission Zero Technologies Expands DAC Technology in Canada
- Elon Musk's xAI Achieves Milestone 19 Days Faster Thanks to Nvidia
- XDLINX Space Labs Pioneering Next-Gen Satellite Solutions Worldwide
- Mastering Market Cycles: Leveraging Valuation Signals
- Bitcoin Surges Amid Mixed Signals from China’s Economy
- Sparinvest Updates Prospectus for Sustainable Investment Fund